Abstract
Huntington’s disease (HD) clinical manifestations begin insidiously and are progressively incapacitating. Symptomatic therapies, in particular dopamine blockers and neuroleptics, are presently the only treatment for HD. Identification of neuropathological mechanisms that underlie the selective striatal and cortical neurodegeneration has allowed for the development of novel neuroprotective therapies that may improve HD patients’ quality of life and enhance their survival. In this review we describe the symptomatic and neuroprotective therapies in HD that are currently in a preclinical or clinical stage. Neuroprotective therapies can act at several stages of HD, namely through: i) transcription modulation, ii) regulation of neurotrophic factors levels, iii) inhibition of metabolic dysfunction through metabolic enhancers, iv) apoptosis inhibition, v) autophagy regulation, vi) transglutaminase inhibition, and/or vii) modulation of neurotransmitter receptors. Moreover, emerging therapies in HD, including gene therapy using siRNA and shRNA to silence CAG repeats or deep brain stimulation, have shown promising results. Although most of the therapies are at a pre-clinical stage, phase II-III clinical trials have been performed for each pathophysiological mechanism of the disease. Thus, efforts should continue to ensure that effective therapies are studied and tested to help mitigate HD.
Keywords: Huntington disease, mutant huntingtin, neuroprotective therapy, symptomatic treatment.
Current Drug Targets
Title:Current Therapeutic Advances in Patients and Experimental Models of Huntington's Disease
Volume: 15 Issue: 3
Author(s): Ana C. Brett, Tatiana R. Rosenstock and A. Cristina Rego
Affiliation:
Keywords: Huntington disease, mutant huntingtin, neuroprotective therapy, symptomatic treatment.
Abstract: Huntington’s disease (HD) clinical manifestations begin insidiously and are progressively incapacitating. Symptomatic therapies, in particular dopamine blockers and neuroleptics, are presently the only treatment for HD. Identification of neuropathological mechanisms that underlie the selective striatal and cortical neurodegeneration has allowed for the development of novel neuroprotective therapies that may improve HD patients’ quality of life and enhance their survival. In this review we describe the symptomatic and neuroprotective therapies in HD that are currently in a preclinical or clinical stage. Neuroprotective therapies can act at several stages of HD, namely through: i) transcription modulation, ii) regulation of neurotrophic factors levels, iii) inhibition of metabolic dysfunction through metabolic enhancers, iv) apoptosis inhibition, v) autophagy regulation, vi) transglutaminase inhibition, and/or vii) modulation of neurotransmitter receptors. Moreover, emerging therapies in HD, including gene therapy using siRNA and shRNA to silence CAG repeats or deep brain stimulation, have shown promising results. Although most of the therapies are at a pre-clinical stage, phase II-III clinical trials have been performed for each pathophysiological mechanism of the disease. Thus, efforts should continue to ensure that effective therapies are studied and tested to help mitigate HD.
Export Options
About this article
Cite this article as:
Brett C. Ana, Rosenstock R. Tatiana and Rego Cristina A., Current Therapeutic Advances in Patients and Experimental Models of Huntington's Disease, Current Drug Targets 2014; 15(3) . https://dx.doi.org/10.2174/1389450114666131124140704
DOI https://dx.doi.org/10.2174/1389450114666131124140704 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Ability of Melatonin to Counteract Lipid Peroxidation in Biological Membranes
Current Molecular Medicine Nano-enhanced Optical Gene Delivery to Retinal Degenerated Mice
Current Gene Therapy End-Stage Dementia Spark of Life: Reliability and Validity of the “GATOS” Questionnaire
Current Alzheimer Research Does Human Alpha-Synuclein Behave Like Prions?
CNS & Neurological Disorders - Drug Targets Artificial Organs: A New Option for Treating Osteoarthritis
Current Drug Delivery The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Investigational Positive Inotropic Agents for Acute Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Determination of Phytochemicals by GC-MS in Two Fractions (17 and 21) of Methanol Extract of Loranthus Micranthus and their Antioxidant and Anti-Inflammatory Activity
The Natural Products Journal Magnetic Resonance Imaging in the Encephalopathic Term Newborn
Current Pediatric Reviews Synthesis and Evaluation of [11C]SB207145 as the First In Vivo Serotonin 5-HT4 Receptor Radioligand for PET Imaging in Man
Current Radiopharmaceuticals Current State of Development of Genome Analysis in Livestock
Current Genomics Mosquito and Tick-borne Illnesses in the United States. Guidelines for the Recognition and Empiric Treatment of Zoonotic Diseases in the Wilderness.
Infectious Disorders - Drug Targets Long Chain n-3 Polyunsaturated Fatty Acids in the Prevention of Allergic and Cardiovascular Disease
Current Pharmaceutical Design Anti-dementia drugs-related changes in gait performance while single and dual tasking in patients with Alzheimer disease: a meta-analysis
Current Alzheimer Research Metabolic Control of Type 2 Diabetes by Targeting the GLUT4 Glucose Transporter: Intervention Approaches
Current Pharmaceutical Design Gain-of-Function Mutations of Receptor Tyrosine Kinases in Gastrointestinal Stromal Tumors
Current Genomics Vascular Endothelial Function Change in Elderly Chinese Patients with Obstructive Sleep Apnea and its Association with Coronary Heart Disease
Vascular Disease Prevention (Discontinued) D2 Receptor Partial Agonists: Treatment of CNS Disorders of Dopamine Function
Current Topics in Medicinal Chemistry Evolution of Antipsychotic Intervention in the Schizophrenic Psychosis
Current Drug Targets Atypical GTPases as Drug Targets
Anti-Cancer Agents in Medicinal Chemistry